Holen Sie sich die Stockscreener-App
1.97
3.90%
-0.08
Handel nachbörslich:
1.95
-0.02
-1.02%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.07
24-Stunden-Volumen:
126.24K
Relative Volume:
0.27
Marktkapitalisierung:
$130.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.20M
KGV:
-0.4724
EPS:
-4.17
Netto-Cashflow:
$-15.98M
1W Leistung:
-31.36%
1M Leistung:
-7.51%
6M Leistung:
+13.87%
1J Leistung:
+123.86%
1-Tages-Spanne:
$1.95
$2.08
1-Wochen-Bereich:
$1.94
$2.89
52-Wochen-Spanne:
$0.7981
$3.82
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
678-392-3419
Adresse
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IKT | 1.97 | 130.23M | 0 | -19.20M | -15.98M | -4.17 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks
Inhibikase Therapeutics Reports Q3 2024 Financial Results - TipRanks
ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) Quarterly 10-Q Report - Quartzy
Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c) - TipRanks
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian
Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com
Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey
Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com
Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India
Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Australia
Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India
Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa
Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com
Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance
Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com
Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN
IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Inhibikase Therapeutics’ $110 Million Private Placement - Global Legal Chronicle
Analyzing the Impact of Earnings Reports on Inhibikase Therapeutics Inc Inc. (IKT) Price Performance - The InvestChronicle
500: Something went wrong - Investing.com
Inhibikase Therapeutics Secures $110M for Drug Development - Yahoo Finance
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) expanding its growth trajectory ahead - SETE News
Inhibikase Therapeutics, Inc. Announces Pricing of $110 Million Private Placement - Marketscreener.com
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline - Yahoo Finance
Inhibikase Therapeutics Inc. (NASDAQ:IKT) Stock Hits 5-Month High On Private Placement - DRP Journal
Inhibikase Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.4198: Will the Stock Break Through? - The InvestChronicle
IKT’s price-to-free cash flow ratio: What it means for investors - US Post News
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today - Benzinga
Inhibikase Therapeutics announces $110 million financing - Investing.com
Inhibikase Therapeutics Announces Pricing of $110 Million - GlobeNewswire
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension - Quantisnow
Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World
Ieq Capital LLC Purchases 2,616 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia
J.W. Cole Advisors Inc. Has $225,000 Holdings in InvenTrust Properties Corp. (NYSE:IVT) - Defense World
Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business - Yahoo Finance
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibikase Therapeutics Inc-Aktie (IKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):